Related Experiment Video
Updated: May 28, 2026

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
Characterization of a bacteriophage, isolated from a cow with mastitis, that is lytic against Staphylococcus aureus
Magdalena Kwiatek1, Sylwia Parasion, Lidia Mizak
1Military Institute of Hygiene and Epidemiology, Lubelska Str. 2, 24-100, Puławy, Poland. magda.kwiatek09@gmail.com
Abstract:
Methicillin-resistant strains of Staphylococcus aureus (MRSA) are now the most commonly reported antibiotic-resistant bacterium in clinical settings. Therefore, there is an urgent need to develop novel antibacterial agents to control this pathogen. Bacteriophage therapy is a potential alternative treatment for MRSA infections. The objective of this study was characterization of a novel virulent bacteriophage (MSA6) isolated from a cow with mastitis. Electron microscopy showed its resemblance to members of the family Myoviridae, with an isometric head (66 nm) and a long contractile tail (173 nm). The genome of phage MSA6 was tested by pulsed-field gel electrophoresis and estimated to be about 143 kb. It exhibited rapid adsorption (>82% in 5 min), a short latent period (15 min) and a relatively small burst size (23 PFU/cell). Isolated phage was capable of infecting a wide spectrum of staphylococcal strains of both human and bovine origin. The results of this investigation indicate that MSA6 is similar to other bacteriophages belonging to the family Myoviridae (Twort, K, G1, 812) that have been successfully used in bacteriophage therapy.
Insights
A novel bacteriophage, MSA6, was characterized for potential use against Methicillin-resistant Staphylococcus aureus (MRSA). This virulent phage shows promise as an alternative therapeutic agent for MRSA infections.
Area of Science:
- Microbiology
- Virology
- Antibiotic Resistance
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of antibiotic-resistant infections.
- Novel therapeutic strategies are crucial to combat the growing threat of MRSA.
- Bacteriophage therapy presents a potential alternative to conventional antibiotics.
Purpose of the Study:
- To characterize a newly isolated virulent bacteriophage, designated MSA6.
- To evaluate the potential of bacteriophage MSA6 as a therapeutic agent against MRSA.
Main Methods:
- Isolation and characterization of bacteriophage MSA6 from a bovine mastitis case.
- Electron microscopy for morphological analysis.
- Pulsed-field gel electrophoresis for genome size estimation.
- Adsorption, latent period, and burst size assays.
- Testing infectivity against a spectrum of staphylococcal strains.
Main Results:
- Phage MSA6 morphology is consistent with the Myoviridae family (isometric head, contractile tail).
- Estimated genome size of phage MSA6 is approximately 143 kb.
- MSA6 demonstrated rapid adsorption (>82% in 5 min), a short latent period (15 min), and a burst size of 23 PFU/cell.
- The phage effectively infected a broad range of staphylococcal strains from human and bovine sources.
Conclusions:
- Bacteriophage MSA6 is a virulent phage with characteristics similar to Myoviridae family members.
- MSA6 shows potential for therapeutic applications against MRSA infections.
- Further investigation into MSA6 efficacy in bacteriophage therapy is warranted.
Related Concept Videos
Lytic Cycle of Bacteriophages
Clinical Significance of Antibiotic Resistance
Lysogenic Cycle of Bacteriophages
DNA Bacteriophages
Viral Replication: Lytic Cycle
Bacteriophages of the Human Virome

